HK1076383A1 - N-((3-oxo2,3-dihydro-1H-isoindol-1-yl)acetyl)guanidine derivatives as nhe-1 inhibitors for the treatment of infaction and angina pectoris - Google Patents

N-((3-oxo2,3-dihydro-1H-isoindol-1-yl)acetyl)guanidine derivatives as nhe-1 inhibitors for the treatment of infaction and angina pectoris

Info

Publication number
HK1076383A1
HK1076383A1 HK05108389A HK05108389A HK1076383A1 HK 1076383 A1 HK1076383 A1 HK 1076383A1 HK 05108389 A HK05108389 A HK 05108389A HK 05108389 A HK05108389 A HK 05108389A HK 1076383 A1 HK1076383 A1 HK 1076383A1
Authority
HK
Hong Kong
Prior art keywords
infaction
oxo2
nhe
isoindol
dihydro
Prior art date
Application number
HK05108389A
Other languages
English (en)
Inventor
Heinz-Werner Kleemann
Armin Hofmeister
Jean-Christophe Carry
Serge Mignani
Antony Bigot
Baptiste Ronan
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HK1076383A1 publication Critical patent/HK1076383A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HK05108389A 2002-06-03 2005-09-23 N-((3-oxo2,3-dihydro-1H-isoindol-1-yl)acetyl)guanidine derivatives as nhe-1 inhibitors for the treatment of infaction and angina pectoris HK1076383A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0206783A FR2840302B1 (fr) 2002-06-03 2002-06-03 Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
PCT/EP2003/005279 WO2003101450A1 (en) 2002-06-03 2003-05-20 N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris

Publications (1)

Publication Number Publication Date
HK1076383A1 true HK1076383A1 (en) 2006-01-20

Family

ID=29558914

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05108389A HK1076383A1 (en) 2002-06-03 2005-09-23 N-((3-oxo2,3-dihydro-1H-isoindol-1-yl)acetyl)guanidine derivatives as nhe-1 inhibitors for the treatment of infaction and angina pectoris

Country Status (42)

Country Link
US (2) US7078428B2 (es)
EP (1) EP1528923B1 (es)
JP (1) JP4634793B2 (es)
KR (1) KR101149771B1 (es)
CN (1) CN1290833C (es)
AR (1) AR039927A1 (es)
AT (1) ATE324889T1 (es)
AU (1) AU2003240677B2 (es)
BR (1) BR0311556A (es)
CA (1) CA2488373C (es)
CY (1) CY1105115T1 (es)
DE (1) DE60305042T2 (es)
DK (1) DK1528923T3 (es)
EC (1) ECSP045472A (es)
EG (1) EG24784A (es)
ES (1) ES2261939T3 (es)
FR (1) FR2840302B1 (es)
HK (1) HK1076383A1 (es)
HN (1) HN2003000162A (es)
HR (1) HRP20041151B1 (es)
IL (1) IL165520A (es)
JO (1) JO2357B1 (es)
MA (1) MA27308A1 (es)
ME (1) MEP27508A (es)
MX (1) MXPA04011931A (es)
MY (1) MY142502A (es)
NO (1) NO329224B1 (es)
NZ (1) NZ536953A (es)
OA (1) OA12864A (es)
PA (1) PA8574701A1 (es)
PE (1) PE20040531A1 (es)
PL (1) PL372188A1 (es)
PT (1) PT1528923E (es)
RS (1) RS51636B (es)
RU (1) RU2318809C2 (es)
SI (1) SI1528923T1 (es)
TN (1) TNSN04237A1 (es)
TW (1) TWI286545B (es)
UA (1) UA81118C2 (es)
UY (1) UY27835A1 (es)
WO (1) WO2003101450A1 (es)
ZA (1) ZA200409094B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531569B2 (en) 2003-12-02 2009-05-12 Sanofi-Aventis Deutschland Gmbh Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives
DE10356717A1 (de) * 2003-12-02 2005-07-07 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von (3-Oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-Derivaten
KR100518184B1 (ko) * 2003-12-27 2005-10-04 한국화학연구원 퓨란카보닐구아니딘 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders
TW200812962A (en) * 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途
SA109300358B1 (ar) 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US8697690B2 (en) 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
TW201321371A (zh) 2011-10-14 2013-06-01 Incyte Corp 做為akt抑制劑之異吲哚啉酮及吡咯并吡啶酮衍生物
CN103193794B (zh) * 2013-04-12 2016-04-06 中国药科大学 一种异吲哚酮并异噁唑类稠环化合物及其合成方法
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
CN106316922B (zh) * 2016-08-17 2019-02-01 华东师范大学 一种含c-3全取代氧化吲哚衍生物及其合成方法和应用
WO2018058109A1 (en) 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN110664803B (zh) * 2019-09-19 2023-08-29 中山大学 异吲哚酮类化合物在制备防治溶骨性疾病药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2107698T3 (es) * 1993-02-20 1997-12-01 Hoechst Ag Benzoilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento, como inhibidores del intercambio celular de na+/h+ o como agente de diagnostico, asi como medicamento que las contiene.
FR2735166B1 (fr) * 1995-06-08 1997-08-29 Aerospatiale Procede de fabrication d'un panneau ou analogue a proprietes structurale et acoustique et panneau ainsi obtenu
DE19737224A1 (de) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
DE19738604A1 (de) * 1997-09-04 1999-03-11 Hoechst Marion Roussel De Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verminderung der Giftigkeit cardiotoxischer Stoffe
SI1056729T1 (en) * 1998-02-27 2005-04-30 Pfizer Products Inc. N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl)guanidine derivatives for the treatment of ischemia
DE19859727A1 (de) * 1998-12-23 2000-06-29 Aventis Pharma Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
JP2003531900A (ja) * 2000-04-28 2003-10-28 ファイザー・プロダクツ・インク I型ナトリウム−水素交換因子(nhe−1)阻害薬
DE10046993A1 (de) * 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
DE60216747T2 (de) * 2001-04-09 2007-10-04 Novartis Vaccines and Diagnostics, Inc., Emeryville Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten

Also Published As

Publication number Publication date
ES2261939T3 (es) 2006-11-16
SI1528923T1 (sl) 2006-08-31
FR2840302B1 (fr) 2004-07-16
US7078428B2 (en) 2006-07-18
PA8574701A1 (es) 2004-05-07
CA2488373C (en) 2012-07-17
TW200404780A (en) 2004-04-01
CN1290833C (zh) 2006-12-20
TWI286545B (en) 2007-09-11
JO2357B1 (en) 2006-12-12
MXPA04011931A (es) 2005-03-31
EG24784A (en) 2010-09-01
NO20045660L (no) 2004-12-27
KR20050010855A (ko) 2005-01-28
MA27308A1 (fr) 2005-05-02
US20060148880A1 (en) 2006-07-06
OA12864A (en) 2006-09-15
DE60305042D1 (de) 2006-06-08
PL372188A1 (en) 2005-07-11
UY27835A1 (es) 2003-12-31
ECSP045472A (es) 2005-01-28
JP2005533034A (ja) 2005-11-04
RS51636B (en) 2011-08-31
TNSN04237A1 (en) 2007-03-12
MEP27508A (en) 2010-06-10
MY142502A (en) 2010-11-30
IL165520A (en) 2009-12-24
IL165520A0 (en) 2006-01-15
ZA200409094B (en) 2005-08-31
ATE324889T1 (de) 2006-06-15
US7589117B2 (en) 2009-09-15
NZ536953A (en) 2007-10-26
CA2488373A1 (en) 2003-12-11
EP1528923A1 (en) 2005-05-11
RU2004138789A (ru) 2005-06-27
BR0311556A (pt) 2005-04-12
WO2003101450A1 (en) 2003-12-11
KR101149771B1 (ko) 2012-06-08
CY1105115T1 (el) 2010-03-03
PE20040531A1 (es) 2004-09-27
DE60305042T2 (de) 2007-05-24
PT1528923E (pt) 2006-08-31
UA81118C2 (en) 2007-12-10
CN1658869A (zh) 2005-08-24
JP4634793B2 (ja) 2011-02-16
HN2003000162A (es) 2004-05-05
AR039927A1 (es) 2005-03-09
EP1528923B1 (en) 2006-05-03
HRP20041151A2 (en) 2005-06-30
US20040048916A1 (en) 2004-03-11
HRP20041151B1 (hr) 2013-06-30
NO329224B1 (no) 2010-09-20
AU2003240677B2 (en) 2008-07-17
AU2003240677A1 (en) 2003-12-19
DK1528923T3 (da) 2006-09-04
RS104804A (en) 2006-12-15
FR2840302A1 (fr) 2003-12-05
RU2318809C2 (ru) 2008-03-10

Similar Documents

Publication Publication Date Title
HK1076383A1 (en) N-((3-oxo2,3-dihydro-1H-isoindol-1-yl)acetyl)guanidine derivatives as nhe-1 inhibitors for the treatment of infaction and angina pectoris
NO20043116L (no) Amidderivater som GK-aktivatorer
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
CY2015053I1 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
IS2895B (is) Bensamíð afleiður gagnlegar sem históndeasetýlasatálmar
EE200300459A (et) Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
NO20043642L (no) Heterocykiske tripeptider som hepatitt C inhibitorer
DK1564210T5 (da) 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
DK1427415T3 (da) Forbindelser indeholdende lactam og derivater heraf som faktor Xa-hæmmere
DK1370554T3 (da) 3-(4-Amidopyrrol-2-ylmethyliden)-2-indolinon-derivater som proteinkinaseinhibitorer
NO20043852L (no) Heterocykliske amidderivater som inhibitorer av glykogen fosforylase
CY2008008I1 (el) Ν-υποκατεστημενοι υδροξυπυριμιδινονο-καρβοξαμιδικοι ανσατολεις της ιντεγρασης hiv
NO20052546D0 (no) Substituert arylthiourea og relaterte forbindelser; inhibitorer av viral reproduksjon.
WO2006050501A3 (en) Novobiocin analogues as anticancer agents
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
DK1549638T3 (da) Indol-3-carboxamider som glucokinase (GK) aktivatorer
IS7509A (is) Þíoxantínafleiður sem mergperoxídasatálmar
HUP0500111A3 (en) Indolinone derivatives useful as protein kinase inhibitors
DK1438289T3 (da) Indolderivater som cox II-inhibitorer
NO20043349L (no) Kumarinderivater, fremgangsmate for deres framstilling og anvendelse derav
DK1511718T3 (da) N-acylaminobenzenderivater som selektive monoaminoxidase B-inhibitorer
PL371439A1 (en) Phthalimido derivatives as inhibitors of monoamine oxidase b
DE60316746D1 (de) Keramischer Suszeptor
MA29038B1 (fr) Derives de n-[(3 s)-pyrrolidine-3-yl]-benzamide servant d'inhibiteurs de reabsorption de monoamines
SI1458713T1 (sl) Uporaba derivatov indolinona kot inhibitorjev kinaz

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150520